The S&P/ASX Small Ordinaries Index closed lower on Tuesday, shedding 6.30 points or 0.17% to finish at 3,645.50. Over the past five days, the benchmark for small-cap stocks has eased just 0.02%.
Despite the softer index performance, several companies have solid announcements this morning. You can read about these and more throughout the day.
Race Oncology makes key scientific discoveries
Race Oncology Ltd (ASX:RAC, OTC:RAONF) announced significant discoveries into the nature of bisantrene, leading to the submission of a new composition of matter patent application. If granted, the patent will protect the chemical structure of the active (E,E)-bisantrene isomer. Two additional patent applications covering manufacturing, formulation, and usage were also filed.
- Bisantrene found to consist of three photoisomers with distinct biological and anticancer activities that interconvert under visible light.
- New manufacturing processes enable controlled infusion of the active (E,E)-bisantrene isomer.
- Three patent applications submitted, potentially providing 20 years of intellectual property protection.
Orthocell introduces Remplir in prostate surgery
Regenerative medicine company Orthocell Ltd (ASX:OCC, OTC:ORHHF) confirmed that its flagship nerve repair device, Remplir, has been introduced to urologists in Australia for use in nerve-sparing Robotic-Assisted Radical Prostatectomies. Remplir has already been deployed in about 40 surgical cases to support the recovery of erectile function and urinary continence.
Orthocell is compiling clinical data from the initial patient group and plans further studies and medical education programs to drive adoption.
archTIS completes retail entitlement offer
archTIS Ltd (ASX:AR9, OTCQB:ARHLF), a global provider of secure collaboration software, announced the successful closing of the retail component of its 1-for-3 pro-rata accelerated non-renounceable entitlement offer. The fully underwritten offer was supported by Henslow Pty Ltd and Canaccord Genuity (Australia) Limited.